
03/03/2025
🔬 MAJOR BREAKTHROUGH IN RETT SYNDROME RESEARCH 🔬
We are proud to announce that CVBF will collaborate as a clinical research service provider for the world's first clinical trial on Mirtazapine for Rett Syndrome!
AIFA Agenzia Italiana del Farmaco - pagina ufficiale has approved the study, coordinated by the Università degli studi di Trieste under the guidance of Prof. Enrico Tongiorgi, which will involve 54 patients aged between 5 and 40 years across four major Italian clinical centers: Milan, Genoa, Siena, and Messina.
CVBF's mission is to facilitate and accelerate the development of medical products with particular attention to special populations, such as paediatric and rare disease ones. This project perfectly aligns with our core values and commitment to advancing treatments for vulnerable patient groups.
Why is this so important?
Rett Syndrome affects 1 in 10,000 girls and is the second leading cause of intellectual disability in female individuals. Currently, there is no definitive cure, but 15 years of research have shown promising results with Mirtazapine, which could improve motor skills, communication abilities, sleep disorders, respiratory and cardiac parameters.
This non-profit study is made possible thanks to the "Angelini for future" project by Angelini Pharma SpA and the generous support of Fondazione Canali Onlus, Ico Falck Onlus, and Amadei e Setti Onlus.
The CVBF team is excited to contribute to this potential therapeutic breakthrough that could significantly improve the quality of life for patients with Rett Syndrome and their families.